Polymer release system
View Patent ↗A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals.
1. A pharmaceutical composition for controlled release of at least one therapeutically active substance into an aqueous medium by erosion of at least one surface of the composition, wherein:
the composition is provided in a dosage form consisting of a single erodible matrix having a coating, wherein:
the single erodible matrix comprises:
(a) one or more polyethylene oxides, wherein the average molecular weight of the one or more polyethylene oxides present in the matrix is from about 200,000 daltons to about 400,000 daltons,
(b) a block copolymer of ethylene oxide and propylene oxide,
(c) a therapeutically active substance, and,
(d) one or more pharmaceutically acceptable excipients selected from the group consisting of cellulose derivatives, release modifiers, and antioxidants, and
the coating has at least one opening exposing at least one surface of said matrix, the coating being insoluble in and impermeable to body fluids,
wherein any matrix surface exposed to an aqueous medium erodes at a substantially constant rate, so that a zero order release is obtained of at least about 60% w/w of the active substance from the pharmaceutical composition over a time period of at least 4 hours when subject to an in vitro dissolution test according to USP 24, NF 19, 711 Dissolution, employing Apparatus 2 equipped with a paddle and wherein aqueous medium is able to diffuse into the matrix with a diffusion rate of 100±30% of the dissolution rate of the matrix in aqueous medium when tested according to USP 24, page 1941-1950.
2. The composition of claim 1 , wherein the one or more polyethylene oxides have an average molecular weight of from about 200,000 daltons to about 300,000 daltons.
3. The composition of claim 1 , wherein the cellulose derivative is selected from the group consisting of microcrystalline cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose and hydroxymethylpropylcellulose.
4. The composition of claim 1 , wherein the cellulose derivative is selected from the group consisting of hydroxypropylmethylcellulose and methyl cellulose.
5. The composition of claim 1 , wherein the cellulose derivative is hydroxypropylmethylcellulose.
6. The composition according to claim 1 , wherein the release modifier is selected from the group consisting of cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, and methacrylic acid copolymers.
7. The composition according to claim 1 , wherein the release modifier is selected from the group consisting of methacrylic acid copolymers.
8. The composition according to claim 1 , wherein the release modifier is selected from the group of methacrylic acid copolymers consisting of methacrylic acid-methyl methacrylate (1:1) and methacrylic acid-methyl methacrylate (1:2) methacrylic acid copolymers.
9. The composition according to claim 1 , wherein the release modifier is selected from methacrylic acid-methyl methacrylate (1:1) methacrylic acid copolymers.
10. The composition of claim 1 , wherein the antioxidant is selected from the group consisting of butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), t-butyl hydroquinone, 1,3,5-trihydroxybenzene , calcium ascorbate, sodium ascorbate, gallic acid, dodecyl gallate, octyl gallate, hydroquinone, maltol, sodium sulfite, sodium bisulfite, sodium metabisulfite, citric acid, tartaric acid, ascorbic acid, erythorbic acid, etidronic acid, phosphite, hypophosphorous acid, nordihydroguairetic acid, propionic acid, potassium bisulphite, potassium metabisulphite, dilauryl thiodipropionate, dimyristyl thiodipropionate, distearyl thiodipropionate, tocopherols, tocopheryl acetates, beta-carotene, ascorbyl palmitate, propyl gallate, sodium formaldehyde sulfoxylate, sodium thiosulfate, sulfur dioxide, tocopherol hemisuccinate.
11. The composition of claim 1 , wherein the antioxidant is selected from the group consisting of BHA and BHT.
12. The composition of claim 1 , wherein the antioxidant is BHT.
13. The composition of claim 1 , wherein the coating comprises one or more polymers selected from the group consisting of cellulose acetate, polyimide, polyethylene, polyethylene terephthalate, polypropylene, polyurethane, polyvinyl acetate, polyvinyl chloride, silicone rubber, latex, polyhydroxybutyrate, polyhydroxyvalerate, teflon, polylactic acid or polyglycolic acid and copolymers thereof, ethylene vinyl acetate (EVA), styrene-butadienestyrene (SBS) and styrene-isoprene-styrene (SIS).
14. The composition of claim 1 , wherein the coating comprises one or more polylactic acid polymers.
15. The composition of claim 13 , wherein the coating further comprises one or more water-soluble crystalline polymers.
16. The composition of claim 1 , having a cylindrical shape optionally with one or more tapered ends.
17. The composition of claim 1 , wherein at least a part of the active substance is in amorphous form.
18. The composition of claim 1 , wherein at least a part of the active substance is in the form of a pharmaceutically active powder.
19. The composition of claim 18 , wherein the powder is comprised of particles with a particle size of from about 0.1 μm to about 500 μm.
20. The composition of claim 1 , wherein at least part of the active substance is present in the form of a solid dispersion.
21. The composition of claim 1 , wherein at least part of the active substance is present as a molecular dispersion.
22. The composition of claim 1 , wherein the coating does not completely crumble or disintegrate before the matrix has completely eroded.
23. A method for administering a therapeutically active substance, comprising orally administering a composition according to claim 1 to a patient in need thereof.
24. A pharmaceutical composition for controlled release of at least one therapeutically active substance into an aqueous medium by erosion of at least one surface of the composition, wherein:
the composition is provided in a dosage form consisting of a single erodible matrix having a coating, wherein:
the single erodible matrix consists essentially of:
(a) one or more polyethylene oxides, wherein the average molecular weight of the one or more polyethylene oxides present in the matrix is from about 200,000 daltons to about 400,000 daltons,
(b) a block copolymer of ethylene oxide and propylene oxide,
(c) a therapeutically active substance, and
(d) one or more pharmaceutically acceptable excipients selected from the group consisting of cellulose derivatives, release modifiers, and antioxidants, and
the coating has at least one opening exposing at least one surface of said matrix, the coating being insoluble in and impermeable to body fluids,
wherein any matrix surface exposed to an aqueous medium erodes at a substantially constant rate, so that a zero order release is obtained of at least about 60% w/w of the active substance from the pharmaceutical composition over a time period of at least 4 hours when subject to an in vitro dissolution test according to USP 24, NF 19, 711 Dissolution, employing Apparatus 2 equipped with a paddle and wherein aqueous medium is able to diffuse into the matrix with a diffusion rate of 100±30% of the dissolution rate of the matrix in aqueous medium when tested according to USP 24, page 1941-1950.